HUT67943A - Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5 - Google Patents

Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5 Download PDF

Info

Publication number
HUT67943A
HUT67943A HU9402293A HU9402293A HUT67943A HU T67943 A HUT67943 A HU T67943A HU 9402293 A HU9402293 A HU 9402293A HU 9402293 A HU9402293 A HU 9402293A HU T67943 A HUT67943 A HU T67943A
Authority
HU
Hungary
Prior art keywords
antibody
sequence
human
seq
monoclonal antibody
Prior art date
Application number
HU9402293A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9402293D0 (en
Inventor
Paul J Zavodny
Mary E Petro
Chuan-Chu Chou
Nicholas J Murgolo
John S Abrams
Chung-Her Jenh
William T Windsor
Jon E Silver
Stephen Tindall
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HU9402293D0 publication Critical patent/HU9402293D0/hu
Publication of HUT67943A publication Critical patent/HUT67943A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HU9402293A 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5 HUT67943A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06

Publications (2)

Publication Number Publication Date
HU9402293D0 HU9402293D0 (en) 1994-10-28
HUT67943A true HUT67943A (en) 1995-05-29

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9402293A HUT67943A (en) 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5

Country Status (21)

Country Link
US (1) US6451982B1 (enEXAMPLES)
EP (1) EP0625201A1 (enEXAMPLES)
JP (2) JPH07505767A (enEXAMPLES)
KR (2) KR0150060B1 (enEXAMPLES)
CN (1) CN1077991A (enEXAMPLES)
AR (1) AR248044A1 (enEXAMPLES)
AU (1) AU683836B2 (enEXAMPLES)
CA (1) CA2129445A1 (enEXAMPLES)
CZ (1) CZ291039B6 (enEXAMPLES)
FI (1) FI943635A0 (enEXAMPLES)
HU (1) HUT67943A (enEXAMPLES)
IL (1) IL104620A (enEXAMPLES)
NO (1) NO942912L (enEXAMPLES)
NZ (1) NZ249633A (enEXAMPLES)
PL (1) PL176393B1 (enEXAMPLES)
RU (1) RU94045919A (enEXAMPLES)
SG (1) SG49597A1 (enEXAMPLES)
SK (1) SK280610B6 (enEXAMPLES)
TN (1) TNSN93012A1 (enEXAMPLES)
WO (1) WO1993016184A1 (enEXAMPLES)
ZA (1) ZA93779B (enEXAMPLES)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104620A (en) 1992-02-06 2000-02-29 Schering Plough Corp Humanized monoclonal antibodies against human interleukin-5
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
HU222992B1 (hu) * 1994-12-23 2004-01-28 Smithkline Beecham Corporation IL-5 Mediált rendellenességek kezelésére használható rekombináns IL-5 antagonisták
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
DE69633973T2 (de) * 1995-09-11 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US7927840B2 (en) * 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
EP1583949B1 (en) * 2002-10-16 2015-06-17 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
RU2366664C2 (ru) 2002-12-17 2009-09-10 Мерк Патент Гмбх Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
WO2006046689A1 (ja) 2004-10-28 2006-05-04 Kyowa Hakko Kogyo Co., Ltd. 子宮内膜症治療剤
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
DK2152290T3 (da) 2007-04-30 2014-08-18 Glaxosmithkline Llc Fremgangsmåder til indgivelse af anti-il-5-antistoffer
CN102026660A (zh) 2008-03-28 2011-04-20 葛兰素史密斯克莱有限责任公司 治疗方法
MX2011003601A (es) * 2008-10-23 2011-04-27 Hoffmann La Roche Determinacion de acido nucleico que codifica inmunoglobulina.
CA2824279A1 (en) * 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
EP2791172B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
AU2015315628A1 (en) 2014-09-08 2017-04-20 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
CN116327923A (zh) 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物
US11390671B2 (en) 2017-06-06 2022-07-19 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
AU2018340557B2 (en) * 2017-09-29 2025-02-27 Jiangsu Hengrui Medicine Co., Ltd. IL-5 antibody, antigen binding fragment thereof, and medical application therefor
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
EP0367596B1 (en) * 1988-11-03 1993-12-22 Schering Corporation Antagonist to interleukin-5 for preventing or reducing eosinophilia
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (en) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
IL104620A (en) 1992-02-06 2000-02-29 Schering Plough Corp Humanized monoclonal antibodies against human interleukin-5

Also Published As

Publication number Publication date
CN1077991A (zh) 1993-11-03
TNSN93012A1 (fr) 1994-03-17
SK280610B6 (sk) 2000-05-16
IL104620A0 (en) 1993-06-10
AR248044A1 (es) 1995-05-31
AU683836B2 (en) 1997-11-27
KR0150060B1 (ko) 1998-08-17
FI943635A7 (fi) 1994-08-05
SG49597A1 (en) 1998-06-15
ZA93779B (en) 1993-08-05
AU3656093A (en) 1993-09-03
JPH07505767A (ja) 1995-06-29
IL104620A (en) 2000-02-29
RU94045919A (ru) 1996-11-10
FI943635L (fi) 1994-08-05
CA2129445A1 (en) 1993-08-07
NZ249633A (en) 1995-12-21
PL176393B1 (pl) 1999-05-31
WO1993016184A1 (en) 1993-08-19
SK91894A3 (en) 1995-02-08
NO942912D0 (enEXAMPLES) 1994-08-05
US6451982B1 (en) 2002-09-17
CZ291039B6 (cs) 2002-12-11
JP2000210097A (ja) 2000-08-02
EP0625201A1 (en) 1994-11-23
KR950700413A (ko) 1995-01-16
FI943635A0 (fi) 1994-08-05
CZ191094A3 (en) 1994-12-15
HU9402293D0 (en) 1994-10-28
NO942912L (no) 1994-10-06

Similar Documents

Publication Publication Date Title
HUT67943A (en) Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
DE69321218T2 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
US6056957A (en) Humanized monoclonal antibodies against human interleukin-5
ES2388837T3 (es) Anticuerpos anti-IL-23p19 diseñados por ingeniería genética
KR100697120B1 (ko) Ｉｌ-18 매개 질환의 치료에 유용한 재조합 ｉｌ-18 길항제
US5846534A (en) Antibodies to the antigen campath-1
US6734286B2 (en) Interleukin-5 specific recombinant antibodies
GB2216126A (en) Antibodies to Campath-1
WO1995001997A1 (en) RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
LU88573A1 (de) Thrombopoietin.
HU230197B1 (hu) Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre
JP2013091636A (ja) Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
JP4550947B2 (ja) ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体
JP2001523083A (ja) Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
DE69504959T2 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
DE69615843T2 (de) Il-8 antagonisten zur behandlung von asthma
JP4648895B2 (ja) 抗ミエリン関連糖タンパク質（ｍａｇ）抗体の治療での使用
CN101448941A (zh) 抗人血小板生成素受体激动剂抗体
HK40057229B (en) Anti-il-17a antibody and use thereof
HK1008831B (en) Cloning and expression of humanized monoclonal antibodies against human interleukin-4
MXPA01009514A (en) Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders